Dao-Rong Wang1, Dong Tang. 1. Department of General Surgery, The First Affiliated Hospital of Yangzhou University, Yangzhou 225001, Jiangsu Province, China. daorong666@sina.com
Abstract
AIM: To investigate the feasibility of detecting hypermethylated secreted frizzled-related protein 2 (SFRP2) gene in fecal DNA as a non-invasive screening tool for colorectal cancer (CRC). METHODS: Fluorescence-based real-time PCR assay (MethyLight) was performed to analyze SFRP2 gene promoter methylation status in a blinded fashion in tumor tissues and in stool samples taken from 69 CRC patients preoperatively and at the 9th postoperative day, 34 patients with adenoma>or=1 cm, 26 with hyperplastic polyp, and 30 endoscopically normal subjects. Simultaneously the relationship between hypermethylation of SFRP2 gene and clinicopathological features was analyzed. RESULTS: SFRP2 gene was hypermethylated in 91.3% (63/69) CRC, 79.4% (27/34) and 53.8% (14/26) adenoma and hyperplastic polyp tissues, and in 87.0% (60/69), 61.8% (21/34) and 42.3% (11/26) of corresponding fecal samples, respectively. In contrast, no methylated SFRP2 gene was detected in mucosal tissues of normal controls, while two cases of matched fecal samples from normal controls were detected with hypermethylated SFRP2. A significant decrease (P<0.001) in the rate of hypermethylated SFRP2 gene was detected in the postoperative (8.7%, 6/69) fecal samples as compared with the preoperative fecal samples (87%, 60/69) of CRC patients. Moreover, no significant associations were observed between SFRP2 hypermethylation and clinicopathological features including sex, age, tumor stage, site, lymph node status and histological grade, etc. CONCLUSION: Hypermethylation of SFRP2 gene in fecal DNA is a novel molecular biomarker of CRC and carries a high potential for the remote detection of CRC and premalignant lesions as noninvasive screening method.
AIM: To investigate the feasibility of detecting hypermethylated secreted frizzled-related protein 2 (SFRP2) gene in fecal DNA as a non-invasive screening tool for colorectal cancer (CRC). METHODS: Fluorescence-based real-time PCR assay (MethyLight) was performed to analyze SFRP2 gene promoter methylation status in a blinded fashion in tumor tissues and in stool samples taken from 69 CRC patients preoperatively and at the 9th postoperative day, 34 patients with adenoma>or=1 cm, 26 with hyperplastic polyp, and 30 endoscopically normal subjects. Simultaneously the relationship between hypermethylation of SFRP2 gene and clinicopathological features was analyzed. RESULTS:SFRP2 gene was hypermethylated in 91.3% (63/69) CRC, 79.4% (27/34) and 53.8% (14/26) adenoma and hyperplastic polyp tissues, and in 87.0% (60/69), 61.8% (21/34) and 42.3% (11/26) of corresponding fecal samples, respectively. In contrast, no methylated SFRP2 gene was detected in mucosal tissues of normal controls, while two cases of matched fecal samples from normal controls were detected with hypermethylated SFRP2. A significant decrease (P<0.001) in the rate of hypermethylated SFRP2 gene was detected in the postoperative (8.7%, 6/69) fecal samples as compared with the preoperative fecal samples (87%, 60/69) of CRC patients. Moreover, no significant associations were observed between SFRP2 hypermethylation and clinicopathological features including sex, age, tumor stage, site, lymph node status and histological grade, etc. CONCLUSION: Hypermethylation of SFRP2 gene in fecal DNA is a novel molecular biomarker of CRC and carries a high potential for the remote detection of CRC and premalignant lesions as noninvasive screening method.
Authors: Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Barry A Turnbull; Michael E Ross Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: C A Eads; R V Lord; K Wickramasinghe; T I Long; S K Kurumboor; L Bernstein; J H Peters; S R DeMeester; T R DeMeester; K A Skinner; P W Laird Journal: Cancer Res Date: 2001-04-15 Impact factor: 12.701
Authors: C A Eads; K D Danenberg; K Kawakami; L B Saltz; C Blake; D Shibata; P V Danenberg; P W Laird Journal: Nucleic Acids Res Date: 2000-04-15 Impact factor: 16.971
Authors: Jürgen Weitz; Moritz Koch; Jürgen Debus; Thomas Höhler; Peter R Galle; Markus W Büchler Journal: Lancet Date: 2005 Jan 8-14 Impact factor: 79.321
Authors: Zsolt Petko; Mahan Ghiassi; Anthony Shuber; Janice Gorham; Walter Smalley; M Kay Washington; Stephen Schultenover; Shiva Gautam; Sanford D Markowitz; William M Grady Journal: Clin Cancer Res Date: 2005-02-01 Impact factor: 12.531
Authors: Yuriko Mori; Alexandru V Olaru; Yulan Cheng; Rachana Agarwal; Jian Yang; Delgermaa Luvsanjav; Wayne Yu; Florin M Selaru; Susan Hutfless; Mark Lazarev; John H Kwon; Steven R Brant; Michael R Marohn; David F Hutcheon; Mark D Duncan; Ajay Goel; Stephen J Meltzer Journal: Endocr Relat Cancer Date: 2011-07-04 Impact factor: 5.678
Authors: Alexandra Kalmár; Bálint Péterfia; Péter Hollósi; Barnabás Wichmann; András Bodor; Árpád V Patai; Andrea Schöller; Tibor Krenács; Zsolt Tulassay; Béla Molnár Journal: Pathol Oncol Res Date: 2015-05-20 Impact factor: 3.201